相关实验视频

Updated: Jul 20, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K

基因组测试用于早期人类表皮生长因子受体2-阳性乳腺癌患者的风险分层

Pier Paolo M Berton Giachetti1,2, Elisa Giordano1,2, Beatrice Taurelli Salimbeni1

  • 1Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS.

Current opinion in oncology
|September 9, 2024
PubMed
概括

像HER2DX这样的新型多基因检测提供了对HER2阳性早期乳腺癌 (EBC) 的预后见解. 这些测试可以预测治疗反应,有助于风险分层和新辅助疗法的潜在降级.

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...